Investigators Identify Predictors of ESA Use in Nondialysis CKD
An analysis of contemporary ESA utilization among patients with anemia of nondialysis-dependent chronic kidney disease may help identify optimal candidates for treatment.
An analysis of contemporary ESA utilization among patients with anemia of nondialysis-dependent chronic kidney disease may help identify optimal candidates for treatment.
Roxadustat reduced the need for rescue therapy among patients with any stage of chronic kidney disease.
Comorbidities and advanced CKD were prevalent among the approximately 275,000 patients with anemia of CKD from the international DISCOVER CKD cohort.
Early detection of iron status may improve cardiovascular risk assessment in patients with CKD, according to investigators.
Investigators sought to define an ESA dosing regimen that reduces the likelihood of transfusion while minimizing any potential cardiovascular risks.
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
Percentage of donations with antibodies has risen steadily over time, according to the Red Cross
Study findings reinforce the value of treating anemia during the transition to dialysis and illustrate the problem of ESA hyporesponsiveness.
The World Kidney Day Steering Committee has declared 2021 the year of “Living Well with Kidney Disease”.
In the CREDENCE trial, patients receiving canagliflozin had reduced risks of initiating iron therapy and erythropoiesis-stimulating agents compared with patients receiving placebo.